Ligand Pharmaceuticals (LGND) Net Income (2010 - 2026)
Ligand Pharmaceuticals (LGND) posted Net Income of -$13.3 million for Q1 2026, down 129.8% sequentially from $44.8 million in Q4 2025, and up 68.56% YoY from -$7.9 million in Q1 2025.
Ligand Pharmaceuticals (LGND) Net Income (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals has reported Net Income for 15 years, with the latest figure at -$13.3 million in Q1 2026.
- Quarterly Net Income rose 68.56% year-over-year to -$13.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $153.6 million (up 308.81% YoY) and the FY2025 annual result came in at $124.5 million, up 3186.63% from the prior year.
- Net Income fell to -$13.3 million in Q1 2026 per LGND's latest filing, from $44.8 million in the prior quarter.
- Over five years, Net Income peaked at $117.3 million in Q3 2025 and troughed at -$42.5 million in Q1 2025.
- A 5-year average of $4.6 million and a median of -$3.0 million in 2022 frame the typical range for Net Income.
- The sharpest annual moves came in 2022 and 2025: Net Income tumbled 136.03% in 2022, then jumped 244.06% in 2025.
- Over 5 years, Net Income stood at -$3.0 million in 2022, then surged by 43.58% to -$1.7 million in 2023, then sank by 1767.15% to -$31.1 million in 2024, then surged by 244.06% to $44.8 million in 2025, then tumbled by 129.8% to -$13.3 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$13.3 million, $44.8 million, and $117.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Ligand Pharmaceuticals | 5.87 Bn | 4.51 Bn | 60.48 Mn | 48.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 48.51 Mn |
| Mar 31, 2026 | -13.35 Mn |
| Dec 31, 2025 | 44.78 Mn |
| Sep 30, 2025 | 117.27 Mn |
| Jun 30, 2025 | 4.85 Mn |
| Mar 31, 2025 | -42.45 Mn |
| Dec 31, 2024 | -31.09 Mn |
| Mar 31, 2023 | -1.67 Mn |
| Dec 31, 2022 | -2.95 Mn |
| Sep 30, 2022 | -9.24 Mn |
| Jun 30, 2022 | -13.49 Mn |
| Mar 31, 2022 | -2.46 Mn |
| Dec 31, 2021 | -2.22 Mn |
| Sep 30, 2021 | -6.62 Mn |
| Jun 30, 2021 | -5.72 Mn |
| Mar 31, 2021 | -4.66 Mn |
| Dec 31, 2020 | 17.59 Mn |
| Sep 30, 2020 | -6.70 Mn |
| Jun 30, 2020 | 22.09 Mn |
| Mar 31, 2020 | -24.13 Mn |